New pyridine derivatives as leptin receptor modulator mimetics

Details for Australian Patent Application No. 2009254552 (hide)

Owner AstraZeneca AB (Publ)

Inventors Simpson, Iain; Higginbottom, Michael; Tyzack, Charles; Horgan, Anne VietAnh; Horton, James

Agent Davies Collison Cave

Pub. Number AU-A-2009254552

PCT Pub. Number WO2009/147216

Priority 61/082,325 21.07.08 US; 0801319-5 04.06.08 SE

Filing date 4 June 2009

Wipo publication date 10 December 2009

International Classifications

C07D 213/30 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4409 (2006.01) - only substituted in position 4, e.g. isoniazid, iproniazid

A61K 31/443 (2006.01)

A61K 31/4439 (2006.01)

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

16 December 2010 PCT application entered the National Phase

  PCT publication WO2009/147216 Priority application(s): WO2009/147216

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009254554-Pharmaceutical combination

2009254550-Inorganic nanoparticles of high density to destroy cells in-vivo